RxDoctor Payments Data

Krzysztof Warszawski, MD

Internal Medicine · Garden City, MINPI 1295711935

Payments from drug & device makers

$412in general payments, 2019–2025

Across 14 payments — averaging $29.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$207
  • Amgen$57
  • GSK$47
  • Dexcom, Inc.$35
  • Exact Sciences$19
  • Pfizer$18
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$207
Amgen3$57
GSK3$47
Dexcom, Inc.2$35
Exact Sciences1$19
Pfizer1$18
Novo Nordisk1$15
AstraZeneca1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$412 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$107,457
Medicare patients
97
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$170,194
EliquisApixaban89$98,861
MounjaroTirzepatide54$73,653
JardianceEmpagliflozin49$56,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$40,307
XareltoRivaroxaban23$32,637
WegovySemaglutide18$29,029
EntrestoSacubitril/Valsartan12$21,345
MyrbetriqMirabegron18$17,258
BrilintaTicagrelor15$17,193
Breo ElliptaFluticasone/Vilanterol28$14,083
Rosuvastatin Calcium316$7,649
Humalog Kwikpen U-100Insulin Lispro14$6,690
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,412
Icosapent Ethyl11$5,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$15$199,223125 claims
PfizerEliquis$18$98,86189 claims
Lilly USA, LLCMounjaro$207$73,65354 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$47$59,80278 claims
AstraZenecaBrilinta$13$17,19315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Garden City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →